Description
Seeking adults with HER2-positive breast cancer who finished chemotherapy plus trastuzumab and breast surgery, and had no cancer found at surgery. This study compares 6 months to 12 months of HER2 medicine to keep cancer from coming back.
Overview
We are studying how long people with HER2-positive breast cancer need to take HER2 medicine after surgery. Everyone gets trastuzumab, with or without pertuzumab. A computer picks whether you take it for about 6 months or about 12 months. Your doctor will then check on you for 10 years.
What we're hoping for
We are studying if 6 months of HER2 medicine works as well as 12 months to keep cancer from coming back for people who have completed chemotherapy plus trastuzumab and breast surgery for HER2-positive breast cancer.
Additional Information
ClinicalTrials.gov Identifier: NCT06876714